肾移植中靶向补体通路的进展与挑战
综述肾移植中补体激活介导的同种异体移植物损伤及靶向治疗进展。C5阻断已革新aHUS移植后管理,C3G复发防治有新药前景,但脑死亡与缺血再灌注损伤的补体干预结果不一,C5阻断对高致敏患者及慢性ABMR进展总体未改善结局,C1抑制剂研究因亚治疗剂量结果令人失望。
要点
- C5阻断已革新肾移植后aHUS的管理。
- 靶向补体放大环路的新药在C3G复发防治中前景可期。
- C5阻断对高致敏患者总体未改善结局且未阻止慢性ABMR进展。
核心结论
- 补体通路在肾移植后同种异体移植物损伤中起关键作用,新型补体阻断剂有望显著减少缺血再灌注、ABMR和肾病复发对移植结局的负面影响。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- C5阻断已革新非典型溶血性尿毒症综合征(aHUS)的移植后管理。
- 靶向补体放大环路的新药在C3肾小球病(C3G)的治疗和预防复发方面前景可期。
- 脑死亡和缺血再灌注后补体通路过度激活已被描述,但减轻后续肾损伤的临床尝试迄今结果不一。
- C5阻断在高致敏患者中总体未能改善结局,也未能阻止向慢性抗体介导排斥(ABMR)的进展。
- C1抑制剂在致敏受者中设计良好的研究迄今结果令人失望,部分因临床研究采用亚治疗剂量。
关键数值与推荐
- C5阻断已革新aHUS的移植后管理,aHUS是补体驱动疾病的范式。
- 靶向补体放大环路的新药在C3G复发治疗和预防方面前景可期。
- 脑死亡和缺血再灌注后补体干预的时机、策略和补体阻断剂类型需优化。
- 体外器官灌注技术为向肾同种异体移植物递送补体靶向药物提供新途径且医源性风险有限。
- C5阻断在高致敏患者中总体未改善结局且未阻止慢性ABMR进展;C1抑制剂在致敏受者中结果令人失望,部分因亚治疗剂量。
临床怎么用
- C5阻断用于肾移植后aHUS管理。
- 靶向补体放大环路的新药用于C3G复发治疗和预防。
- 脑死亡和缺血再灌注后补体干预需优化时机、策略和阻断剂类型。
- 体外器官灌注技术可递送补体靶向药物至肾同种异体移植物。
- 高致敏患者C5阻断和C1抑制剂疗效有限,C1抑制剂需注意剂量不足问题。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The complement system is paramount in the clearance of pathogens and cell debris, yet is increasingly recognized as a key component in several pathways leading to allograft injury. There is thus a growing interest in new biomarkers to assess complement activation and guide tailored therapies after kidney transplantation (KTx). C5 blockade has revolutionized post-transplant management of atypical hemolytic uremic syndrome, a paradigm of complement-driven disease. Similarly, new drugs targeting the complement amplification loop hold much promise in the treatment and prevention of recurrence of C3 glomerulopathy. Although unduly activation of the complement pathway has been described after brain death and ischemia reperfusion, any clinical attempts to mitigate the ensuing renal insults have so far provided mixed results. However, the intervention timing, strategy, and type of complement blocker need to be optimized in these settings. Furthermore, the fast-moving field of ex vivo organ perfusion technology opens new avenues to deliver complement-targeted drugs to kidney allografts with limited iatrogenic risks. Complement plays also a key role in the pathogenesis of donor-specific ABO- and HLA-targeted alloantibodies. However, C5 blockade failed overall to improve outcomes in highly sensitized patients and prevent the progression to chronic antibody-mediated rejection (ABMR). Similarly, well-conducted studies with C1 inhibitors in sensitized recipients yielded disappointing results so far, in part, because of subtherapeutic dosage used in clinical studies. The emergence of new complement blockers raises hope to significantly reduce the negative effect of ischemia reperfusion, ABMR, and nephropathy recurrence on outcomes after KTx.
引用
- Golshayan D, Schwotzer N, Fakhouri F, et al. Targeting the Complement Pathway in Kidney Transplantation. J Am Soc Nephrol. 2023. PMID: 37439664. doi:10.1681/ASN.0000000000000192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。